Conferences
Stay informed about upcoming pharma conferences, symposiums, and events. Discover opportunities to connect with industry experts, thought leaders, and researchers. Stay updated about the latest scientific advancements, networking opportunities, and educational programs in the pharmaceutical field.
New drug Enhertu shows promise for HER2-mutant lung cancer patients (IASLC WCLC 2023 Conference)
The International Association for the Study of Lung Cancer (IASLC) presented pivotal results from the DESTINY-Lung02 Phase II trial at ...
Merck showcases new data on sotatercept for PAH, awaits FDA decision
Merck & Co. has unveiled new clinical data on sotatercept, reinforcing the drug candidate’s safety and efficacy in the treatment ...
BMS scores another phase 2 win for its pulmonary fibrosis drug
Bristol Myers Squibb (BMS) is making significant strides in the field of pulmonary fibrosis treatment, particularly with its lysophosphatidic acid ...
Amgen Unveils Exciting First-Line KRAS G12C NSCLC Data: Lumakras (Sotorasib) with Chemotherapy Shines at WCLC
Amgen has unveiled exciting findings from a segment of the CodeBreaK 101 clinical trial, a Phase 1b study investigating the ...
Datopotamab Deruxtecan + Imfinzi Transform First-Line NSCLC Treatment in TROPION-Lung04 Trial
The TROPION-Lung04 Phase Ib trial has unveiled highly promising results. The trial showcases the potential of datopotamab deruxtecan (Dato-DXd), in ...
Novartis Unveils Breakthrough Long-Term Data: Leqvio Sustains LDL-C Reduction Beyond Six Years in ESC 2023
In the world of medical innovation, where the quest to tame cardiovascular risk is a relentless endeavor, Novartis unfurls a ...
BridgeBio Exposes Phase 3 Acoramidis Insights, Mortality Figures
In the intricate dance of scientific exploration, BridgeBio has taken a resolute plunge into the depths of phase 3 acoramidis ...
Unveiling the Intricate Symphony: AstraZeneca’s Farxiga at the Heart of Cardiorenal Insights
In the heart of Amsterdam, amidst the captivating backdrop of the European Society of Cardiology (ESC) scientific sessions, AstraZeneca wielded ...
Exploring Real-World Anticoagulant Transitions: Insights Unveiled at the European Society of Cardiology (ESC) Congress 2023
Amidst the vivid tapestry of medical advancements, a pivotal revelation has emerged from the collaborative efforts of the Bristol Myers ...
Amgen’s Groundbreaking Discovery: Unleashing the Potential of Olpasiran Beyond Expectations
In a revelation that promises to reshape the landscape of cardiovascular health, biotechnology giant Amgen has unveiled extraordinary findings from ...
Gilteritinib and Allo HSCT Together Increase Survival in FLT3-Mutated AML
Results from a real-world study presented at the European Society for Blood and Marrow Transplantation (EBMT) 49th Annual Meeting indicate ...
Patients prefer ViiV’s injectable HIV medication, according to a Switch research
When ViiV Healthcare and Johnson & Johnson introduced their once-monthly injectable HIV treatment Cabenuva in 2021, they anticipated that patients ...
Twice-Yearly Lenacapavir Boosts HIV Patients’ Quality of Life
Source – Gilead Gilead Sciences presented new data at the 12th International AIDS Society (IAS) Conference on HIV Science (IAS ...
Eisai Unveils Lecanemab’s Alzheimer’s Breakthrough at AAIC 2023
Source – Eisai July 20, 2023 Biogen revealed the results of a comprehensive analysis of the Phase III Clarity AD ...
Cervical Cancer: Frontline SHR-1701 Plus BP102 and Chemo Shows Potent Activity
The combination of the novel bifunctional fusion protein SHR-1701 with bevacizumab (BP102) and platinum-doublet chemotherapy has shown promising results in ...
At the AAIC, Alnylam presents a long-acting amyloid medication
Source – Alnylam Pharmaceuticals Alnylam has presented promising preliminary clinical results for its new RNA interference candidate, ALN-APP, which targets ...
Donanemab Shows Significant Advance in Alzheimerās Treatment
Source – Eli Lilly The full data from Eli Lilly’s TRAILBLAZER-ALZ 2 trial of the amyloid drug donanemab has validated ...
Apellisā Syfovre Linked to Eye Inflammation in Geographic Atrophy Patients
Source – Apellis Pharmaceuticals July 17, After receiving FDA approval for the treatment of advanced eye disease geographic atrophy, Apellis ...
Advanced RCC Tumor Sequencing Identifies Host Signatures Associated with Immunotherapy Response
In a single-center study presented at the 2023 Kidney Cancer Research Summit, researchers found that patients with metastatic renal cell ...
Treatment for Advanced HNSCC With ASP-1929 and Anti-EGFR Therapy Is Effective
Source – Rakuten Medical Promising early results have been observed with ASP-1929, in combination with anti-PD-1 therapy, for patients with ...
Positive new Phase III MRI results from the NMOSD study UPLIZNA
Source – Horizon Therapeutics Horizon Therapeutics unveiled positive MRI data from a Phase III clinical trial of UPLIZNA (inebilizumab) at ...
A recent study demonstrates the efficacy of the digital Dario tool in managing severe diabetes
Source – DarioHealth A joint effort between DarioHealth and Sanofi has yielded promising results in a real-world study presented at ...
Novo Nordisk and Eli Lilly Drive Breakthroughs in Oral GLP-1 Treatments for Obesity at ADA Conference
Novo Nordisk and Eli Lilly showcased advancements in the development of oral GLP-1 treatments for Type II diabetes and obesity ...
Promising Early Antitumor Activity of Camrelizumab Plus Famitinib in Advanced Melanoma
A Phase II trial presented at the 2023 ASCO Annual Meeting showed that combining the PD-L1 inhibitor camrelizumab with the ...
TAK-755 Prophylaxis Shows Promise in Managing cTTP: ISTH 2023 Congress Highlights
Source – Takeda On June 25, 2023, Takeda has shared promising interim findings from a global Phase III clinical trial ...
Vera Therapeutics Atacicept Shows Efficacy and Safety in IgAN at ERA Congress
Soure: Vera Therapeutics On June 17, 2023, Vera Therapeutics, a biotechnology company focused on immunological diseases, announced positive results from ...
Adcetris Breakthrough: Six-Year Survival Data Reinforce Its Impact in Hodgkin Lymphoma Treatment
Seagen has made a significant announcement regarding the updated U.S. Prescribing Information (PI) for Adcetris (brentuximab vedotin). The update includes ...
Ziftomenib: A Promising New Treatment for NPM1-Mutated Acute Myeloid Leukemia
Kura Oncology’s recent presentation at the European Hematology Association (EHA) 2023 conference highlighted the impressive clinical potential of ziftomenib in ...
2023 EASL Congress: Gilead to Present New Liver Disease Research
According to Gilead Sciences new data will be presented at the 2023 European Association for the Study of the Liver ...
At EASL 2023, Merck will present data on the investigational GLP-1/glucagon receptor co-agonist Efinopegdutide (MK-6024) in patients with non-alcoholic fatty liver disease (NAFLD)
Source- Merck NJ-RAHWAY Efinopegdutide (MK-6024), an investigational GLP-1/glucagon receptor co-agonist, has new findings that have been accepted for oral presentation ...
